EGFR and lung carcinoma: The survival time of lung cancer patients bearing common EGFR mutations (Exon 19 deletion or L858R point mutation) has been markedly improved with the FDA approval of first-generation EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib [154].